These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17370637)

  • 21. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
    van de Donk NW; Kröger N; Hegenbart U; Corradini P; San Miguel JF; Goldschmidt H; Perez-Simon JA; Zijlmans M; Raymakers RA; Montefusco V; Ayuk FA; van Oers MH; Nagler A; Verdonck LF; Lokhorst HM
    Blood; 2006 Apr; 107(8):3415-6. PubMed ID: 16597603
    [No Abstract]   [Full Text] [Related]  

  • 22. Multiple myeloma: charging toward a bright future.
    Katzel JA; Hari P; Vesole DH
    CA Cancer J Clin; 2007; 57(5):301-18. PubMed ID: 17855486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the treatment of MDS, multiple myeloma, and CLL.
    Snively A
    ONS Connect; 2007; 22(8 Suppl):55-6. PubMed ID: 17824566
    [No Abstract]   [Full Text] [Related]  

  • 24. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
    Björkstrand B; Gahrton G
    Semin Hematol; 2007 Oct; 44(4):227-33. PubMed ID: 17961721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progress in the treatment of multiple myeloma.
    Kumar S
    Lancet; 2006 Mar; 367(9513):791-2. PubMed ID: 16530557
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
    [No Abstract]   [Full Text] [Related]  

  • 27. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Chim CS
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
    [No Abstract]   [Full Text] [Related]  

  • 28. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
    Lonial S; Cavenagh J
    Br J Haematol; 2009 Jun; 145(6):681-708. PubMed ID: 19344388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Velcade for multiple myeloma. A new method of administration].
    Perspect Infirm; 2012; 9(5):66. PubMed ID: 22978139
    [No Abstract]   [Full Text] [Related]  

  • 30. Multiple myeloma patient care: treatment options and nursing considerations.
    McGee L
    ONS Connect; 2007; 22(8 Suppl):67-8. PubMed ID: 17824572
    [No Abstract]   [Full Text] [Related]  

  • 31. Pleural and pericardial effusion as the first sign of multiple myeloma.
    André M; Ponsonnaille J; Kemeny JL; Filaire M; Travade P; Aumaitre O
    Ann Med Interne (Paris); 1999 Sep; 150(5):443-5. PubMed ID: 10544757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of multiple myeloma: a systematic review and critical appraisal of published studies.
    Kumar A; Loughran T; Alsina M; Durie BG; Djulbegovic B
    Lancet Oncol; 2003 May; 4(5):293-304. PubMed ID: 12732167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.
    Braiteh F; Hymes SR; Giralt SA; Jones R
    J Clin Oncol; 2008 Sep; 26(27):4511-3. PubMed ID: 18802165
    [No Abstract]   [Full Text] [Related]  

  • 34. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In focus: (166) Ho-DOTMP in the pretransplant treatment of multiple myeloma.
    Clapp K
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):753-4. PubMed ID: 16170894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infiltration of the spinal cord in a patient with multiple myeloma.
    Varettoni M; Corso A; Zappasodi P; Calliada F; Castagnola C; Mangiacavalli S; Lazzarino M
    J Clin Oncol; 2008 Sep; 26(25):4207-9. PubMed ID: 18757337
    [No Abstract]   [Full Text] [Related]  

  • 38. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
    Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
    J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of multiple myeloma in patients with Gaucher disease.
    Machaczka M; Lerner R; Klimkowska M; Hägglund H
    Am J Hematol; 2009 Oct; 84(10):694-6. PubMed ID: 19743447
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical updates and nursing considerations for patients with multiple myeloma.
    Faiman B
    Clin J Oncol Nurs; 2007 Dec; 11(6):831-40. PubMed ID: 18063542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.